Call us at (888) 828-2206. We'll help answer any questions you may have.
ALLO-1715 is an allogeneic (donor-derived) CAR T cell therapy targeting B-cell maturation antigen (BCMA) that is being developed as a potential novel treatment for multiple myeloma and other BCMA-positive malignancies.
April 15, 2019
You can give us a call at (888) 828-2206 or create your account to add this treatment to your list of favorites. We'll send you alerts when this treatment is updated.
Create My Account